Cigna (CI) Reports Q4 Earnings: What Key Metrics Have to Say

Cigna (CI) reported $72.5 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 10.4%. EPS of $8.08 for the same period compares to $6.64 a year ago.The reported revenue represents a surprise of +3.66% over the Zacks Consensus Estimate of $69.93 billion. With the consensus EPS estimate being $7.87, the EPS surprise was +2.7%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Cigna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Medical Care Ratio - Cigna Healthcare: 88% versus the six-analyst average estimate of 87.2%.Covered Lives By Market Segment - Medical Customers - International Health: 1.7 million compared to the 1.72 million average estimate based on three analysts.Medical Customers - Total: 18.12 million versus the three-analyst average estimate of 18.09 million.Medical Customers - U.S. Healthcare: 16.42 million compared to the 16.38 million average estimate based on three analysts.Revenues- Net investment income: $339 million versus $262.89 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +22.4% change.Revenues- Cigna Healthcare: $11.15 billion compared to the $10.92 billion average estimate based on four analysts. The reported number represents a change of -16.2% year over year.Revenues- Evernorth Health Services: $63.06 billion versus $59.19 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +17.3% change.Revenues- Pharmacy: $58.34 billion versus $56.03 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +16.8% change.Revenues- Fees and Other: $4.51 billion versus the four-analyst average estimate of $4.4 billion. The reported number represents a year-over-year change of +14.8%.Revenues- Premiums: $9.29 billion compared to the $8.94 billion average estimate based on four analysts. The reported number represents a change of -19.3% year over year.Revenues- Cigna Healthcare- Premiums: $9.12 billion versus $8.99 billion estimated by three analysts on average.Revenues- Cigna Healthcare- Net investment income: $205 million compared to the $119.09 million average estimate based on three analysts.View all Key Company Metrics for Cigna here>>>Shares of Cigna have returned -2.7% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cigna Group (CI): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks